Glycogen storage disease type ia
Drug research and approvals for glycogen storage disease type ia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 5 studies of glycogen storage disease type ia are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, and FDA has 1 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 5
- Trials authorized in Canada: 5
- FDA orphan approvals: 1
- EU medicines: 0
- Accuracy of Home Lactate Meter and Accu-chek Glucometer in Patients With Glycogen Storage DiseaseNCT07459582 · Not reported · Connecticut Children's Medical Center · starts Sep 18, 2026
- Dietary Treatment Strategies and Metabolic Control in Glycogen Storage Disease Type INCT06852612 · Not applicable · Insel Gruppe AG, University Hospital Bern · starts Apr 24, 2025
- Accuracy of Lactate Meter in GSDIaNCT06843330 · Not reported · Connecticut Children's Medical Center · starts Apr 14, 2025
- A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage…NCT06735755 · Phase 1 / Phase 2 · Beam Therapeutics Inc. · starts Dec 6, 2024
- Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring ProgramNCT06636383 · Not reported · Ultragenyx Pharmaceutical Inc · starts Nov 4, 2024
| May 27, 2022 | An open-label dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MRNA-3745 in participants with glycogen…MRNA-3745 | Modernatx, Inc. | Closed |
| Oct 8, 2021 | A phase 3, randomized, double-blind, placebo-controlled study of adenoassociated virus serotype 8-mediated gene transfer of glucose-6- phosphatase in patients…DTX401(AAV8G6PC) / Prednisolone | Ultragenyx Pharmaceutical | Closed |
| Jun 1, 2021 | A phase 1/2 first-in-human, 2-part study to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses (part 1: open-label) and repeat…UX053 | Ultragenyx Pharmaceutical | Closed |
| Jun 4, 2020 | A long-term follow-up study to evaluate the safety and efficacy of adeno-associated virus (AAV) serotype 8 (AAV8)-mediated gene transfer of…DTX401 (AAV8G6PC) | Ultragenyx Pharmaceutical | Closed |
| Jun 29, 2018 | A phase 1/2, open-label safety and dose-finding study of adeno-associated virus (AAV) serotype 8 (AAV8)-mediated gene transfer of glucose-6-phosphatase…DTX401 (AAV8G6PC) | Ultragenyx Pharmaceutical | Closed |
| Aug 19, 2026 | GenglycosTo reduce daily cornstarch intake as an adjunct to nutritional management in adult and pediatric patients 8 years of age and older with… | Ultragenyx Pharmaceutical, Inc. | Approved |
| Mar 11, 2013 | AAV-G6Pase vectorTreatment of glycogen storage disease type Ia | GlyGenix Therapeutics, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA